Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | PRKACA | P17612 | 3/20 | 0.33 |
| ▸ | TYMS | P04818 | 3/20 | 0.33 |
| ▸ | GART | P22102 | 3/20 | 0.33 |
| ▸ | ATIC | P31939 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210939 | 0.92 | ADORA3 (0.40) | EPHX2ADORA3ADORA2AADORA1PRKACA | |
| SCHEMBL13210962 | 0.92 | ADORA3 (0.33) | FOLH1EPHX2ADORA3ADORA2AADORA1 | |
| SCHEMBL13211010 | 0.91 | FOLH1 (0.38) | FOLH1EPHX2ADORA3ADORA2AADORA1 | |
| SCHEMBL13210961 | 0.87 | ADORA3 (0.39) | EPHX2ADORA3ADORA2AADORA1PRKACA | |
| SCHEMBL14384561 | 0.83 | ADORA3 (0.41) | EPHX2ADORA3ADORA2AADORA1PRKACA | |
| SCHEMBL13211031 | 0.83 | ADORA3 (0.34) | FOLH1EPHX2ADORA3ADORA2AADORA1 | |
| SCHEMBL13210959 | 0.83 | ADORA3 (0.36) | ADORA3ADORA2AADORA1 | |
| SCHEMBL14384567 | 0.83 | ADORA3 (0.41) | EPHX2ADORA3ADORA2AADORA1PRKACA | |
| SCHEMBL13211027 | 0.78 | ADORA3 (0.40) | EPHX2ADORA3ADORA2AADORA1PRKACA | |
| SCHEMBL14387176 | 0.78 | ADORA3 (0.40) | EPHX2ADORA3ADORA2AADORA1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | FOLH1 802/4885EPHX2 267/4885ADORA3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.